06.05.2020 17:06
In partnership with BioMarin Pharmaceutical Inc., DiNAQOR, a gene therapy platform company will develop novel gene therapies to treat rare genetic heart diseases. As part of this preclinical collaboration and license agreement, the startup will receive an upfront payment as well as development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales.